Access Pharmaceuticals Receives Notice of AMEX Delisting

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ask Centralassd	LSE:AKCA	London	Ordinary Share	GB0034031905	ORD 5P(ASSD CITY CENTRE REST SHS & CASH)

Share Name

Share Symbol

Market

Type

Share ISIN

Share Description

Ask Centralassd

LSE:AKCA

London

Ordinary Share

GB0034031905

ORD 5P(ASSD CITY CENTRE REST SHS & CASH)

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

Industry Sector

Turnover

Profit

EPS - Basic

PE Ratio

Market Cap

N/A

Access Pharmaceuticals Receives Notice of AMEX Delisting

31/01/2006 9:30pm

PR Newswire (US)

Ask Centralassd (LSE:AKCA)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Ask Centralassd Charts.

DALLAS, Jan. 31 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (AMEX:AKC) today announced its receipt of an American Stock Exchange ("AMEX") Listing Qualifications Department determination denying the Company's appeal of an AMEX Staff Determination on December 12, 2005 which found that the Company failed to comply with AMEX's continued listing standards due to losses from continuing operations and/or net losses in two of its most recent fiscal years with shareholders' equity of less than $2 million, as set forth in Section 1003(a)(i) of the AMEX "Company Guide"; due to losses from continuing operations and/or net losses in three of its most recent fiscal years with shareholders' equity of less than $4 million, as set forth in Section 1003(a)(ii) of the Company Guide; and due to losses from continuing operations and/or net losses in four of its most recent fiscal years with shareholders' equity of less than $6 million, as set forth in Section 1003(a)(iii) of the Company Guide. As a result, Access Pharmaceuticals, Inc.'s common stock is expected to be delisted from AMEX effective with the open of business on Wednesday, February 1, 2006. Access Pharmaceuticals, Inc.'s quotation for its common stock is expected to appear in the "Pink Sheets" under the trading symbol "AKCA" on or about February 1, 2006. Access also expects that its common stock will be quoted in the future on the OTC Bulletin Board, provided that a market maker files the necessary application with the NASD and such application is cleared. While the delisting determination is obviously disappointing, we continue to actively seek to close a financing, merger or licensing option. Access Pharmaceuticals, Inc. is an emerging pharmaceutical company developing unique polymer linked cytotoxics for use in the treatment of cancer. Its lead product AP5346 is in Phase II clinical testing. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including but not limited to statements made relating to our listing on the American Stock Exchange, our expected quotation in the Pink Sheets and possible future quotation on the OTC Bulletin Board as well as our activity seeking financing, merger or licensing. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2004, Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 and other reports filed by us with the Securities and Exchange Commission. DATASOURCE: Access Pharmaceuticals, Inc. CONTACT: Stephen B. Thompson, Vice President & CFO of Access Pharmaceuticals, Inc., +1-214-905-5100; or investor relations, Donald C. Weinberger of Wolfe Axelrod Weinberger LLC, +1-212-370-4500, for Access Pharmaceuticals, Inc.

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AKCA Ask Centralassd